BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $66.35 million. The enterprise value is $49.49 million.
| Market Cap | 66.35M |
| Enterprise Value | 49.49M |
Important Dates
The next estimated earnings date is Wednesday, August 28, 2024, before market open.
| Earnings Date | Aug 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 79.94 million shares outstanding.
| Shares Outstanding | 79.94M |
| Owned by Insiders (%) | 8.54% |
| Owned by Institutions (%) | 1.76% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.69 |
| Forward PS | n/a |
| PB Ratio | 5.08 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.87.
| Current Ratio | 1.14 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.64 |
Financial Efficiency
Return on equity (ROE) is -325.10% and return on invested capital (ROIC) is -187.33%.
| Return on Equity (ROE) | -325.10% |
| Return on Assets (ROA) | -86.50% |
| Return on Capital (ROIC) | -187.33% |
| Revenue Per Employee | $147,532 |
| Profits Per Employee | -$622,127 |
| Employee Count | 79 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.77% in the last 52 weeks. The beta is 0.88, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -48.77% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 68.03 |
| Average Volume (20 Days) | 372,914 |
Short Selling Information
| Short Interest | 324,292 |
| Short Previous Month | 212,051 |
| Short % of Shares Out | 0.45% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.96 |
Income Statement
In the last 12 months, BioLineRx had revenue of $11.66 million and -$49.15 million in losses. Loss per share was -$0.05.
| Revenue | 11.66M |
| Gross Profit | 6.51M |
| Operating Income | -45.66M |
| Pretax Income | -49.15M |
| Net Income | -49.15M |
| EBITDA | -44.96M |
| EBIT | -46.98M |
| Loss Per Share | -$0.05 |
Balance Sheet
The company has $28.17 million in cash and $11.31 million in debt, giving a net cash position of $16.86 million or $0.21 per share.
| Cash & Cash Equivalents | 28.17M |
| Total Debt | 11.31M |
| Net Cash | 16.86M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 13.06M |
| Book Value Per Share | 0.16 |
| Working Capital | 4.32M |
Cash Flow
In the last 12 months, operating cash flow was -$28.70 million and capital expenditures -$116,000, giving a free cash flow of -$28.82 million.
| Operating Cash Flow | -28.70M |
| Capital Expenditures | -116,000 |
| Free Cash Flow | -28.82M |
| FCF Per Share | -$0.40 |
Margins
Gross margin is 55.84%, with operating and profit margins of -391.76% and -421.69%.
| Gross Margin | 55.84% |
| Operating Margin | -391.76% |
| Pretax Margin | -421.69% |
| Profit Margin | -421.69% |
| EBITDA Margin | -385.71% |
| EBIT Margin | -403.06% |
| FCF Margin | -247.25% |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.73% |
| Shareholder Yield | -17.73% |
| Earnings Yield | -74.07% |
| FCF Yield | -43.43% |
Analyst Forecast
The average price target for BioLineRx is $21.00, which is 2,430.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 2,430.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 15, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jul 15, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
BioLineRx has an Altman Z-Score of -12.26 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.26 |
| Piotroski F-Score | 2 |